Journals / IUFS Journal of Biology / 2008 / Cilt: 67 - Sayı: 1

Effect of adriamycin administered via different routes on ehrlich ascites tumor cells

Pages
49–54
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The most efficient in respect of curing properties was observed in group I in which ADR administered via intraperitoneal.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Adriamycin (ADR) is an antineoplastic drug, isolated from Streptomyces peucetius var. caesius, and has cytotoxic features.
📊
Key Findings & Data:The aim of our study is to investigate the effectiveness of ADR on mice bearing EAT by comparing its administration routes. 0.01 mg.g-1 ADR was administered mice bearing EAT via intraperitoneal, intravenous and subcutaneous.
💡
Conclusion & Impact:The most efficient in respect of curing properties was observed in group I in which ADR administered via intraperitoneal.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Adriamycin (ADR) is an antineoplastic drug, isolated from Streptomyces peucetius var. caesius, and has cytotoxic features. It binds DNA by intercalation and inhibits replication and transcription. Clinically, ADR is used intravenously and intravesically. Ehrlich ascites tumor (EAT) was originated from breast carcinoma in a mouse. It grows in solid and ascitic forms. The aim of our study is to investigate the effectiveness of ADR on mice bearing EAT by comparing its administration routes. 0.01 mg.g-1 ADR was administered mice bearing EAT via intraperitoneal, intravenous and subcutaneous. On day 0 each mouse in the experiment was inoculated with 3x105 EAT cells. On the $2^ {nd} 4^ {th}6^ {th} 8^{th}$ days after administration, number of viable cells and mitosis number were counted from each animal by drainage the ascites fluid from the peritoneal cavity of each mouse. Data were evaluated statistically. The most efficient in respect of curing properties was observed in group I in which ADR administered via intraperitoneal.

🔖

Cite This Article

GÜMÜŞHAN, H., MUSA, D. (2022). Effect of adriamycin administered via different routes on ehrlich ascites tumor cells. IUFS Journal of Biology, Cilt: 67 - Sayı: 1, 49–54. https://ajindex.com/articles/544079

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C. and Spalla C. (1969) 14-Hydroxydaunomycin, a new antibiotic from Streptomyces peucetius var. caesius. Biotechnology and Bioengineering, 11: 1101-1110.
  2. Asaumi J., Nishikawa K., Matsuoka H., Iwata M., Kawasaki S., Hiraki Y. and Nishijima K. (1995) Direct antitumor effect of cepharantin and combined effect with adriamycin against Ehrlich ascites tumor in mice. Anticancer Research, 15 (1): 67-70.
  3. Bancroft J.D., Stevens A. and Turner D.R. (1990) Theory and Practice of Histological Techniques. 3rd Edn., Longman Group UK Limited, Great Britain, pp:37, 148-189.
  4. Barranco S.C., Gerner E.W., Burk K.H. and Humphrey R.M. (1973) Survival and cell kinetics effects of adriamycin on mammalian cells. Cancer Research., 33: 11-16.
  5. Booser D.J. and Hortobagyı G.N. (1994) Anthracycline antibiotics in cancer therapy. Drugs, 47 (2): 223-258.
  6. Bowers D.G. and Lynch J.B. (1978) Adriamycin extravasation. Plastic & Reconstructive Surgery, 61 (1): 86-92.
  7. Ivic M.A., Petrovic S.D., Kalman E., Milosavljevic T., Reljin I., Reljin B., Bogdanovic G., Baltic V.V. and Keresztes Z. (2005) AFM studies of DNA structures extracted from adriamycin treated and non-treated Ehrlich tumor cells. Journal of Serbian Chemical Society, 70 (6): 823-831.
  8. Kaleoğlu Ö. and İşli N. (1977) Ehrlich-Lettré Asit Tümörü. İstanbul Üniversitesi Tıp Fakültesi Mecmuası, 40: 978-984.
  9. Kayaalp, O. (1996) Tıbbi Farmakoloji, 2nd Edn, Hacettepe Taş Kitapçılık, Ankara, ISBN: 975-7731-23-4, pp.79. Kim, S.H., Kim, J.H. (1972) Lethal effect of Adriamycin on the division cycle of HeLa cells. Cancer Research, 32: 323-325.
  10. Lefrak, E.A., Pitha, J., Rosenheim, S. and Gottlieb, J.A. (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32:302-314.
  11. Luedke, D.W., Kennedy, P.S. and Rietschel, R.L. (1979) Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plastic & Reconstructive Surgery, 63 (4): 463-465.
  12. Malviya, V.K., Deppe, G., Boike, G. and Young, J. (1990) Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. Gynecologic Oncology, 36: 185-188.
  13. Mazzotta, P., Kwasnicka, A. and Kutas, G.J. (2001) Cancer Chemotherapy: The role of pharmacological agents in the management of haematological malignancies. University of Toronto Medical Journal, 79 (1): 38-45.
  14. Mimaki Y., Shinozawa S., Yasuda K., Yao K., Etwo K., Fukuda T. and Araki Y. (1